Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay
1. Moderna lowers 2025 revenue outlook by $300 million due to UK vaccine delays. 2. Firm projects 2025 revenue between $1.5 billion and $2.2 billion. 3. Second-quarter loss of $2.13 per share; revenue dropped 41% year-over-year. 4. Shares fell 8% after forecast cut and have lost over a third this year. 5. Stock down nearly 95% since post-pandemic peak in September 2021.